undamentalytics Newsletter
Sign in

Insight Molecular Diagnostics Inc. balance sheet

At the end of fiscal 2025, Insight Molecular Diagnostics Inc. had total assets of $25.8m, total liabilities of $57.2m and shareholders' equity of −$31.5m. It held $11.6m in cash against $0 of debt.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2015Dec 20152020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents873320991218
Receivables—0120210
Inventory—————000
Total current assets119392611121521
Goodwill—919—————
Total assets135516010075352629
Accounts payable00211232
Total current liabilities291412771210
Total debt0—000000
Total liabilities222946049475751
Shareholders' equity1033653420−12−31−21
Non-controlling interests and other (assets − liabilities − equity)———55———
Shares outstanding—69m92m6m8m—29m33m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: ICU vs IMDXFEMY vs IMDXIMDX vs PLSE

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Insight Molecular Diagnostics Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Insight Molecular Diagnostics Inc.